TrialPediatric nephrology (Berlin, Germany)2017

A randomised Phase I/II trial to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria.

Bernd Hoppe et al.PubMed ↗Publisher ↗

No numbers read from the abstract.